Governing Biotechnology
By George Annas,
Global Agenda Magazine
| 02. 13. 2006
Developments in biotechnology have made possible species-changing and even species-endangering procedures, says George Annas. We urgently need a global governance structure to regulate them.
Albert Einstein cogently observed that "imagination is more important than knowledge." He could have gone further. Moral imagination is more important than scientific imagination. The unmet challenge for science at the beginning of the 21st century is to develop a global bioethics governance system that can help to ensure that biomedical technology enhances human life, and does not degrade or end it.
Paradoxically, the global biotechnology research agenda is facing backwards and forwards at the same time. Looking back, we are trying to react to threats of global pandemics, bioterrorism, and biowarfare. Looking forwards, we are striving to use new biomedical technologies not only to cure or prevent disease but also to physically modify humans in ways that could change our concept of humanity.
So far the world is taking governance of backward-looking technologies more seriously than the forward-looking ones. This is probably because the world has had lots of experience of pandemics and war, because...
Related Articles
By Rob Stein, NPR [cites CGS' Katie Hasson] | 08.06.2025
A Chinese scientist horrified the world in 2018 when he revealed he had secretly engineered the birth of the world's first gene-edited babies.
His work was reviled as reckless and unethical because, among other reasons, gene-editing was so new...
By Kristel Tjandra, Genetic Engineering & Biotechnology News | 07.30.2025
CRISPR has taken the bioengineering world by storm since its first introduction. From treating sickle cell diseases to creating disease-resistant crops, the technology continues to boast success on various fronts. But getting CRISPR experiments right in the lab isn’t simple...
By Arthur Caplan and James Tabery, Scientific American | 07.28.2025
An understandable ethics outcry greeted the June announcement of a software platform that offers aspiring parents “genetic optimization” of their embryos. Touted by Nucleus Genomics’ CEO Kian Sadeghi, the $5,999 service, dubbed “Nucleus Embryo,” promised optimization of...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...